Category Archives: Public Policy

Latest From Public Policy

2012: A Critical Year for Biotechnology

U.S. Capitol Building - Congress

In 2012, we must continue to look for ways to reduce risk; enhance reward; reduce uncertainty; and reinforce the position of the industry as a major contributor resolving society’s most pressing needs. Policies to encourage investment in innovation and to speed discovery to scientific breakthroughs simply must be the priority in 2012. The industry relies on a policy and regulatory environment that encourages innovation for much needed treatments and cures for some of the most Read More >

Public Policy  |  1 Comment  |  Email This Post
Tags: , , , , , ,

Biomedical Innovation: How the U.S. Can Stay Number One

lab_tech02-thumb

By Ross DeVol, chief research officer of the Milken Institute “The first step in winning the future is encouraging American innovation,” declared President Obama in his last State of the Union speech. A logical place to start is making sure that where we hold a lead, we keep it. Today, the U.S. has such a lead in biomedical innovation — the process of transforming scientific discoveries into vaccines, diagnostics, devices and therapies that improve and Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Biotech Remains Strong in Florida

FLbiotech-thumb

Florida has always attracted visionaries – from Walt Disney to Kennedy Space Center. The ambition of great men helped transform inhospitable swamps into engines of the economy. However, with no income tax, and a large retiree population, Florida’s revenue long depended on booming tourism and the sales tax revenue it brought in. In the 1990’s, Florida’s leaders began to change that. Enterprise Florida was born. This public/private partnership was designed to identify and provide incentives Read More >

Public Policy  |  1 Comment  |  Email This Post
Tags: , , , ,

NIH Licensing Efforts Target Start-Ups

NIH_Logo

The National Institutes of Health (NIH) has developed a new short-term licensing arrangement they hope will encourage licensing of NIH and FDA inventions to start-up companies.  The NIH Start-Up Exclusive License Agreements targets start-up companies less than 5 years old, with less than $5M in raised capital, and fewer thans than 50 employees.  By offering an exclusive license, they hope to accelerate the technology transfer process.  However, this temporary pilot program runs only until September 30, Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO Supports SBIR Reauthorization in Senate

Capitol

Last week, the Senate passed the National Defense Authorization Act (S. 1867), which included SBIR reauthorization through Senate Amendment 1115. This is a critical step toward ensuring that all innovative companies can compete for SBIR grants – based on the promise of their science rather than the structure of their capital.  Reauthorizing the program to allow small companies that receive the majority of their financing from venture capital to once again be eligible to compete Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , ,